New obesity pill Foundayo wins FDA approval, offering easier alternative to injections
The FDA has approved Foundayo, a new oral obesity drug from Eli Lilly and the second GLP‑1 pill to reach the U.S. market. Clinical trials showed patients lost an average of 7.5% of their body weight, with the highest dose producing 11.2% loss—less than injectable drugs like Wegovy, but with key advantages. Unlike earlier GLP‑1 pills, Foundayo doesn’t require fasting or meal‑timing, making it easier for patients to take consistently. Doctors say that convenience could improve long‑term adherence. The most common side effects are gastrointestinal.